Design Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
DSGN$10.21+5.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations
(in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development (including related party amounts of $0, $228, $72 and $686, respectively) | $16,926 | $14,589 | $47,693 | $45,704 |
| General and administrative (including related party amounts of $60, $130, $205 and $395, respectively) | 5,304 | 4,722 | 16,420 | 15,594 |
| Total operating expenses | 22,230 | 19,311 | 64,113 | 61,298 |
| Loss from operations | (22,230) | (19,311) | (64,113) | (61,298) |
| Interest income | 1,942 | 2,314 | 6,024 | 7,503 |
| Net loss | $(20,288) | $(16,997) | $(58,089) | $(53,795) |
| Net loss per share, basic and diluted | $(0.32) | $(0.30) | $(0.93) | $(0.95) |
| Weighted-average shares of common stock outstanding, basic and diluted | 63,035,529 | 56,950,999 | 62,330,974 | 56,856,779 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.